ReviewCureus2026
Propofol and Hypertriglyceridemia in the ICU: A Systematic Review and Meta-Analysis of Recent Observational Data.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While previous expert consensus guidelines by the American College of Critical Medicine recommend serum triglyceride monitoring after two consecutive days of propofol, the most recent Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption guidelines do not address monitoring triglyceride levels in patients on continuous propofol infusions. Recent cohort studies have shown that a majority of patients on continuous propofol lack triglyceride measurements. Our objective was to systematically summarize and compare the reported incidence of pancreatitis, hospital length of stay (LOS), intensive care unit (ICU) LOS, and hospital mortality in patients on continuous propofol infusions who developed hypertriglyceridemia (HTG) compared with those without HTG. Methods included Medical Subject Headings terms and keywords were used to construct a systematic search according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines involving PubMed, Embase, Web of Science, Cochrane, and Cumulative Index to Nursing and Allied Health Literature (CINAHL). Inclusion criteria were papers published in English, since 2000, involving ICU patients ≥18 years old, who were on continuous propofol infusions. Six of the 790 studies identified (2,301 patients) were included. Pooled incidence of HTG was 28% with an average onset of 4.3 days. Both ICU LOS (pooled standardized mean difference (SMD) = 0.37, 95% CI: (0.16, 0.58), p < 0.0001, I² = 47%) and hospital LOS (pooled SMD = 0.21, 95% CI: (0.06, 0.35), p < 0.0001, I² = 0%) were increased in patients who developed HTG. Pooled incidence of pancreatitis was 1.3% with no significant difference between groups. In conclusion, HTG in ICU patients requiring continuous propofol infusions was associated with increased ICU and hospital LOS, with no significant differences in pancreatitis incidence or mortality. While this does not demonstrate causality due to its retrospective nature, it does point to an association of worse outcomes and hypertriglyceridemia in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.